Yeah, it's all about the phase 2 trial, which is a 9 months to...

Yeah, it's all about the phase 2 trial, which is a 9 months to one year timeframe. I think the main time determinant is enrolling the number of patients required for a statistically significant sample size. Given that this is a double blind study, they won't know which patients got the Xtoll treatment and which got the placebo until the trial ends. So I don't see there being many updates until the study is over, apart from say the number of patients enrolled in the study.

So in that sense it's a bit like drilling an oil well, and I'm expecting the share price to behave like a spec oil stock over the next year. We're in the low volume/high volatility Christmas period now, so there might be the opportunity to pick up stock at a lower price from a forced seller, but it's a bit of a punt. I'm set now and looking forward to the results of the trial.

Merry Christmas everyone,
redfloyd